Feedback / Questions
SRSD107 - Sirius Therap, CRISPR Therap
https://www.globenewswire.com/news-release/2025/09/22/3153917/0/en/CRISPR-Therapeutics-and-Sirius-Therapeutics-Announce-First-Patient-Dosed-in-Phase-2-Trial-of-SRSD107-for-Thromboembolic-Disorders-in-Europe.html
Sep 22, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next